Allogene Therapeutics, Inc. (ALLO)
Last updated: 2026-10-21 23:40:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Allogene Therapeutics, Inc. (ALLO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.33, with a market capitalization of $449.14M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.04 to $4.46. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$449.14M | |
$1.33 | |
$55.00 | |
$0.86 | |
$1.33 | |
4.35M | |
5.72M | |
-- | |
$4.46 | |
$1.04 | |
-- | |
-- |
Allogene Therapeutics, Inc. (ALLO) After-Hours Stock Price
Allogene Therapeutics, Inc. (ALLO) is trading at $1.35 in after-hours trading as of 2026-10-21 23:31:00, up 1.13% ($0.01) from the regular-session close of $1.33.
After-hours trading shows how investors are pricing ALLO after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Allogene Therapeutics, Inc. (ALLO) 7-Day Stock Price Change
Over the past seven days, Allogene Therapeutics, Inc. (ALLO) moved from $1.40 to $1.33, representing a decline of 5.36% ($0.07).
The stock traded between $1.22 and $1.46 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 5.50 million shares, down versus the previous seven-day period, indicating lower trading activity.
ALLO 52-Week Price Position
Position in Range: 8.3%
ALLO is currently trading at $1.33, placing it 8.3% of the way from its 52-week low of $1.04 to its 52-week high of $4.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Allogene Therapeutics, Inc. (ALLO)?
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Allogene Therapeutics, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 152 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Allogene Therapeutics, Inc. (ALLO) Stock on MEXC
Eligible investors can buy real shares of Allogene Therapeutics, Inc. (ALLO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Allogene Therapeutics, Inc. (ALLO) stock price today?
2.Is ALLO stock going up or down today?
3.What is ALLO pre-market price?
4.What is ALLO after-hours price?
5.Is ALLO stock trading now?
6.Where does ALLO sit relative to its 52-week high and low?
7.What sector is Allogene Therapeutics, Inc. in?
8.What is Allogene Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is ALLO valued in terms of P/E ratio and EPS?
10.Does Allogene Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
ALLO Stock Calculator
Estimate the value between ALLO shares and USD.
ALLO Shares to USD
1.00 ALLO shares = 1.325 USD
Calculations are estimates based on the latest available price and are for reference only.


